文献速递脑血管病

机械取栓与桥接治疗前循环大血管闭塞卒中:系统综述与Meta分析

Mechanical Thrombectomy vs Bridging Therapy for Anterior Circulation Large Vessel Occlusion Stroke: Systematic Review and Meta-analysis.
PubMed 文献 · Neurology · 2022-02-16

该系统综述与Meta分析纳入41项研究共14885例前循环大血管闭塞卒中患者,比较桥接治疗(BT)与单纯机械取栓(MT)的疗效与安全性。整体分析显示BT组功能独立、成功再通和死亡结局的比值比均优于MT组,但限制于6项随机对照试验(n=2333)时,功能独立、症状性颅内出血和死亡率无显著差异,成功再通仍 favoring BT组。作者指出需进一步开展随机对照试验。

要点

  • 整体数据(41项研究,14885例)中,BT组功能独立OR 1.29(95%CI 1.16-1.44),成功再通OR 1.25(95%CI 1.08-1.44),死亡OR 0.69(95%CI 0.60-0.80)。
  • 限制于6项RCT(n=2333)时,功能独立、症状性颅内出血和死亡率组间无显著差异。
  • RCT亚组中成功再通仍 favoring BT组,OR 1.35(95%CI 1.06-1.73)。

核心结论

  • 整个数据集的功能独立、成功再通和死亡结局的比值比 favoring BT而非MT(中等异质性、低质量证据)。
  • 限制于RCT时,两种治疗的功能和安全性结局相似(无异质性),但再通率 favoring BT组(无异质性)。
  • 作者指出,这些发现可能不适用于直接就诊于无MT能力中心的患者或使用其他溶栓药物的患者,需进一步开展RCT。

研究设计与样本

  • 系统检索生物医学文献数据库,从建库至2021年10月29日,纳入比较MT与BT的前瞻性和回顾性研究。
  • 共纳入41项研究、14885例患者;BT组平均年龄69±11岁,MT组70±11岁。
  • 所有研究均使用阿替普酶作为溶栓药物;其中6项为随机对照试验(RCT),在直接就诊于具备MT能力中心的患者中进行了意向性治疗分析(n=2333)。
  • 效应量以比值比(OR)表示,采用随机效应Meta分析;异质性通过I²和Cochrane Q统计量评估。

主要发现

  • 与MT相比,BT组功能独立 odds 高29%(OR 1.29,95%CI 1.16-1.44,I²=42%),成功再灌注 odds 高25%(OR 1.25,95%CI 1.08-1.44,I²=42%),死亡 odds 降低31%(OR 0.69,95%CI 0.60-0.80,I²=47%)。
  • 症状性颅内出血(sICH)发生率两组相似(OR 1.10,95%CI 0.95-1.28,I²=0%)。
  • 限制于6项RCT(n=2333)时,功能独立(OR 1.08,95%CI 0.91-1.27,I²=0%)、sICH(OR 1.37,95%CI 0.95-1.97,I²=0%)和死亡率(OR 0.93,95%CI 0.74-1.16,I²=0%)组间无差异。
  • RCT亚组中成功再灌注 favoring BT组(OR 1.35,95%CI 1.06-1.73,I²=0%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 整个数据集的分析显示中等异质性(功能独立I²=42%,成功再灌注I²=42%,死亡I²=47%)和低质量证据。
  • 作者指出,这些发现可能不适用于直接就诊于无MT能力中心的患者或使用其他溶栓药物的患者。
  • 作者指出需进一步开展RCT。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Current guidelines recommend the use of mechanical thrombectomy (MT) plus IV thrombolysis (aka bridging therapy [BT]) for patients with anterior circulation large vessel occlusion (LVO) stroke. However, clinical equipoise exists in relation to the use of BT vs MT alone. Our objective is to compare the efficacy and safety of BT and MT for anterior circulation LVO. METHODS: A systematic search of biomedical literature databases was performed from inception to October 29, 2021, to identify prospective and retrospective studies comparing the rates for functional independence (modified Rankin Scale score 0-2) and mortality at 90 days, symptomatic intracranial hemorrhage (sICH), and successful recanalization rates for MT and BT. Effect size was represented by odds ratio (OR), and analysis was done with random-effects meta-analysis. Heterogeneity was assessed by I 2 and Cochrane Q statistics. RESULTS: Overall, 41 studies with 14,885 patients were included. Mean ± SD age was 69 ± 11 years for BT and 70 ± 11 years for MT. All studies used alteplase as the thrombolytic agent. The BT group had 29% higher odds for functional independence (OR 1.29, 95% CI 1.16-1.44, I 2 = 42%), 25% higher odds of successful reperfusion (OR 1.25, 95% CI 1.08-1.44, I 2 = 42%), and 31% decrease in odds for mortality (OR 0.69, 95% CI 0.60-0.80, I 2 = 47%) compared with MT. sICH prevalence was similar between groups (OR 1.10, 95% CI 0.95-1.28, I 2 = 0%). Six of the studies were randomized controlled trials (RCTs) with intention-to-treat analysis done in patients presenting directly to MT-capable centers. When analysis was restricted to these 6 RCTs (n = 2,333), no differences were observed in functional independence (OR 1.08, 95% CI 0.91-1.27, I 2 = 0%), sICH (OR 1.37, 95% CI 0.95-1.97, I 2 = 0%), or mortality (OR 0.93, 95% CI 0.74-1.16, I 2 = 0%) between groups. However, successful reperfusion favored the BT group (OR 1.35, 95% CI 1.06-1.73, I 2 = 0%). DISCUSSION: The odds for functional independence, successful reperfusion, and mortality for the entire dataset favored the use of BT over MT (medium heterogeneity and low quality of evidence). When analysis was restricted to RCTs, both treatments had similar functional and safety outcomes (no heterogeneity), but recanalization rates favored the BT group (no heterogeneity). Because these findings may differ in patients who present to non-MT-capable centers or with the use of other thrombolytic agents, further RCTs are needed.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Trifan G, Biller J, Testai FD, et al. Mechanical Thrombectomy vs Bridging Therapy for Anterior Circulation Large Vessel Occlusion Stroke: Systematic Review and Meta-analysis. Neurology. 2022. PMID: 35173017. doi:10.1212/WNL.0000000000200029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。